$2.30
+9.52%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.15
From 52W high−58.03%
Volume3.88M
Market cap$183.27M
P/E (TTM)—
P/S (TTM)122.5x
Div yield—
Key dataSep 18, 2026
Open
$2.15
From 52W high
−58.03%
Volume
3.88M
Market cap
$183.27M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
P/E (TTM)
—
RSI (14)
59.2
MomentumView details →
1D Return
+9.52%
YTD Return
−22.61%
SummaryUpdated Jun 1, 2026
Tharimmune, Inc. (NASDAQ:THAR) is a clinical-stage biotechnology company founded in 2017 and headquartered in Bridgewater, New Jersey. The company was originally incorporated as Hillstream BioPharma, Inc. before changing its name to Tharimmune in September 2023. Since going public in January 2022, Tharimmune has focused on developing therapeutic candidates targeting rare diseases, inflammatory conditions, and various forms of cancer. The company operates in the highly specialized and capital-intensive biotechnology sector, where drug development timelines typically span many years and require substantial investment before generating any revenue.
Similar companies
Latest newsMore news →
Canton Strategic Holdings, Inc. released its financial and operating results for the second quarter ended June 30, 2026, reporting first operating revenue from locking service and Super Validator operations and completing the sale of its legacy biotechnology subsidiary Gravitas.37d agoTheeb Rent A Car secured board approval on 5 August 2026 to establish a new limited liability subsidiary in Bahrain, 99% owned by the company and 1% by CEO Naif Mohammed Al Theeb, to provide car rental services in the Bahraini market.45d agoCanton Strategic Holdings, Inc. elected Sean Galvin, Pamela L. Carter, and Rishi Nangalia as directors to its Board of Directors, effective July 13, 2026.54d ago